secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2024-12-19T23:59:59+00:00
Accession:  0001079973-24-001742
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq grants TOI additional 180 days to meet $1 minimum bid price through June 16, 2025
--------------------------------------------------------------------------------

- Received Second Nasdaq Bid Price Letter on Dec 19, 2024 granting extension to June 16, 2025.
- Company must regain compliance with minimum $1.00 bid price by end of Second Compliance Period.
- May consider a reverse stock split to cure deficiency; split must be completed 10 business days before deadline.
- If compliance not met, Nasdaq will issue delisting notice; Company may appeal to Nasdaq Hearings Panel.
- No immediate effect on listing or trading of common stock (TOI) or warrants (TOIIW).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000107997324001742/0001079973-24-001742-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000107997324001742/toi_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-24-001742

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer